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MINI REVIEW
Engineered kidneys: principles, progress, and prospects
Jamie A. Davies*, C-Hong Chang, Melanie L. Lawrence, Christopher G. Mills
and John J. Mullins
Centre for Integrative Physiology and Centre for Synthetic Biology, University of Edinburgh,
Edinburgh, UK
There is an urgent need for new ways to treat end-stage renal disease: by promoting regeneration in situ,
by repopulating decellularized donor organs with a patient’s own stem cells, or by making entirely new
kidneys. There are two broad strategies for making new kidneys: precision engineering by positioning
everything exactly  for example, by 3D printing  or supporting cells’ self-organizing ability. We describe the
latter approach, which begins with a suspension of renogenic stem cells and produces a small kidney with
nephrons, a collecting duct system, active transport, and an ability to integrate with host vasculature. Many
problems have to be solved before these kidneys are directly clinically useful, including size, maturation,
provision of a ureter, and production from human-induced pluripotent stem cells. Even the existing
engineered kidneys, if they can be made from human rather than animal cells, may be useful for assays for
adverse drug reactions that will be free of the problems of extrapolating from animal tests to predicted human
responses.
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E
nd-stage renal disease is a serious and common
morbidity. Patients are treated by dialysis or trans-
plantation: dialysis is a medium-term lifesaver but
is uncomfortable, restrictive, and time-consuming for the
patient. Transplantation is much more satisfactory, and
a transplant provides the full range of renal function,
though immunosuppressive drugs can produce serious
side effects. The main problem is availability, both in terms
of the total number (in most countries, the number of
organs offered is less than half of the demand) and in terms
of an individual finding a close enough immunological
match. Various strategies are being pursued to improve
availability, from social (e.g. moving to presumed consent)
to immunological (developing techniques to promote
toleration of less precise tissue type matches). Never-
theless, a serious transplantation gap remains.
There is therefore much interest applying stem cell
based regenerative medicine to renal failure. There are
four potential approaches: pharmacological encourage-
ment of regeneration in situ by endogenous stem cells,
regeneration in situ by application of exogenous stem
cells, repopulation of a decellularized postmortem kidney
with fresh stem cells, and construction of a complete,
new, transplantable kidney. This review will concentrate
only on the fourth, but excellent reviews on the first three
approaches can be found elsewhere (14).
Engineering a kidney de novo
Kidneys are anatomically complex. Human kidneys have
100,0002,000,000 nephrons, each of which consists of a
glomerulus and a sequence of tubular segments that drains
into a multibranched collecting system. The segments
of the nephron are arranged in an anatomically precise
way, starting in the cortex, then dipping down into
the medulla and back: this arrangement is necessary for
efficient water recovery. There is also an extensive blood
system that makes very fine filtration structures in
the glomeruli and a countercurrent loop parallel to the
medullary loops of the nephrons. In addition, stromal and
neural cells support the tubules and relay physiological
signals within the kidney and beyond. The task of
engineering a kidney is therefore challenging  far more
so than, for example, making a sheet of cartilage.
Approaches to meeting this challenge can be divided
into two types. In one, spatial information is provided
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from outside. A model of the desired organ might, for
example, be programmed into a computer connected to
a three-dimensional (3D) printer that can print extracel-
lular matrix loaded with the correct type of cell. Simple
biological structures have been made by electrospinning
and 3D printing (5, 6), but nothing anywhere near as
complex as a kidney has yet been described in the peer-
reviewed research literature, although a very promising
account of unpublished work presented at a meeting has
appeared in the blog of a learned journal (7).
The other strategy relies on cells’ own capacity to
organize themselves, as they do in embryonic develop-
ment. In this approach, engineers’ involvement is limited
to providing a permissive environment (chemical and
physical). This approach is the main topic of this review.
The first experiments in renal self-organization used
the only certain source of renogenic stem cells: disag-
gregated embryo kidneys (alleged renal stem cells made
from embryonic stem (ES) and induced pluripotent stem
(iPS) cells do exist, but they have been identified only
through markers, and not their developmental potential
has not been fully verified). Making a suspension of
mouse fetal renogenic cells and simply reaggregating
them, in the presence of drugs that suppress anoikis, are
sufficient for a substantial degree of self-organization
to take place. Nephron progenitors form and produce
distinct, correctly ordered segments, and collecting duct
stem cells make multiple small collecting duct trees (8).
A serial technique, in which a first, multi-tree kidney is
engineered as above, and then just one of those small
trees is combined with a suspension of fresh nephrogenic
stem cells, results in the arrangement of nephrons around
a single tree, as they should be (9).
Recent years have seen the development of a new
culture system that allows intact fetal kidney rudiments
to produce distinct cortex and medulla, and loops of
Henle, in culture (10). In this system, the engineered
organs behave similarly (Fig. 1a) (11). Furthermore,
when transferred to chick egg chorioallantoic membrane
(12) or adult rat hosts (13), engineered kidneys become
vascularized. Their proximal tubules also display active
transport in culture (Fig. 1b).
The next challenges
Though excited by the complexity and realism of the
organs that can be engineered using this approach, we
readily acknowledge that they are currently far from being
clinically useful. In no particular order, they have the
following problems: they are small; they are flat (only
about 100 mm thick, although millimeters in diameter);
they have no exit for urine; they are murine, not human;
and they come from fetal stem cells (human fetuses cannot
ethically be harvested for making new organs).
Small size and flatness may be mitigated by growth
inside the eventual host. The engineered kidney seemed to
become more 3D in the rat host experiment (13), and effort
might be applied usefully in promoting in vivo growth
in all directions. Lack of a urine exit might be solved
Fig. 1. Recent progress in renal tissue engineering. (a) shows
an engineered ‘fetal kidney’ made by reaggregation of a
suspension of isolated fetal renogenic stem cells, followed by
culture in an environment conducive to organotypic devel-
opment. The organ formed has an outer cortex (Ctx), with
nephrons with glomerular clefts (gc). The nephrons send
loops of Henle (LoH) into the otherwise nephron-free
medulla (M), while a branched collecting duct system (cd)
ramifies throughout. The red stain is anti-laminin, which
shows basement membranes of all renal tubules. There is
not, though, any ureter through which the kidney can drain.
(b) shows an assay for a key renal physiological function
in engineered kidneys  active organic anion uptake by
proximal tubule cells. Here it is demonstrated by concentra-
tion of 6-carboxyfluorescein (green) in the proximal tubule
(Pt) cells: the red channel shows peanut agglutinin, which
stains renal basement membranes. (c) demonstrates that fetal
ureters can survive and grow in vitro, elongating markedly
between day 0 and day 4 of culture. An important next step
is to engineer these from simple cell suspensions and connect
them to engineered kidneys.
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by combining the existing engineering technique with
techniques for tissue engineering ureters: there are now
promising ways of growing natural (fetal) ureters in
culture (Fig. 1c). We are working collaboratively on the
problem of replacing fetal mouse stem cells with repro-
grammed mouse ES or iPS cells. The first stage is to use
mixtures of allegedly reprogrammed ES or iPS cells and
the fetal renogenic cells to test the developmental potential
of the reprogrammed cells (14), then to go to all ES- or
iPS-derived systems. Some progress has been made toward
both of these aims (15, 16).
Applications other than renal replacement
Even when we (or any other group) can make engineered
kidneys, whether by self-organization or by printing, there
will need to be extensive safety testing before they
can be applied clinically to real human patients. There is
one potential application that does not need any advance
beyond what we have already achieved, except that it
requires the engineering to be done with reprogrammed
human iPS cells rather than fetal mouse ones. Engineered
human kidneys in culture (even small and flat one) could
give the pharmaceutical and chemical industries a much
more realistic in vitro assay for assessing the risks of
nephrotoxicity in humans. This is important. Especially in
the elderly, a significant proportion of renal disease is
iatrogenic, mostly caused by adverse reactions to drugs,
particularly nonsteroidal anti-inflammatory drugs and
antibiotics, or other drugs in complex combinations (17).
Currently, preclinical risk assessment for nephrotoxicity is
based on a combination of crude human cell line assays
and animal testing. The cell lines currently available reflect
natural kidney function only poorly (18). Primary cultures
of human proximal tubule cells are more realistic in
metabolic terms (19), but they are hard to obtain, relying
on postmortem or resection material that comes directly
from a hospital. Animal tests are physiologically realistic
for that animal but not necessarily for humans. Meta-
analyses of the predictive power of animal testing for
human toxicity (i.e. ‘adverse drug reaction’) has shown
that human responses are predicted correctly about
1050% of the time (20, 21). This is a terrible statistic:
not only does it mean that a vast amount of resources is
wasted on developing drugs that have to be withdrawn
following phase IIV trials, but also it means that some
candidate drugs that would in fact be safe and effective
in humans are wrongly abandoned because of alarming
animal data. Having small but physiologically realistic
human kidneys in culture would be a major step forward.
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